DAUNOPLUS 20mg powder for injection medication leaflet

L01DB02 daunorubicin • Antineoplastic and immunomodulating agents | Cytotoxic antibiotics and related substances | Anthracyclines and related substances

Daunorubicinum is a chemotherapy drug used for the treatment of acute leukemia, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It belongs to the anthracycline class and works by inhibiting DNA synthesis in cancer cells, preventing their division.

The medication is administered intravenously and is often used in combination with other chemotherapy drugs to enhance treatment effectiveness. It is effective in inducing remission in patients with acute leukemia.

Side effects may include nausea, vomiting, hair loss, bone marrow suppression, and an increased risk of infections. In rare cases, it may cause cardiac toxicity. Close monitoring is essential during treatment.

Consult your doctor to discuss the benefits and risks of treatment with Daunorubicinum. Follow all medical recommendations to minimize associated risks.

General data about DAUNOPLUS 20mg

Substance: daunorubicin

Date of last drug list: 01-05-2025

Commercial code: W70654001

Concentration: 20mg

Pharmaceutical form: powder for injection

Quantity: 1

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: VHB MEDI SCIENCES LIMITED - INDIA

Holder: BESMAX PHARMA SOLUTIONS S.R.L. - ROMANIA

Number: 993/2024/01

Concentrations available for daunorubicin

20mg, 20mg/10ml

Other substances similar to daunorubicin

Combinations with other substances